# | Aladdin ID | Assay Type | Description | Organism | Compounds | Reference | BAO Format | Source | |
---|---|---|---|---|---|---|---|---|---|
1. | ALA5052966 | B | Inhibition of Arid5a in human HEK293T cells at 40 uM assessed as inhibition of stabilization of IL-6 on 3'UTR measured by luciferase assay | Homo sapiens | 4 | ALA5052828 | cell-based format | Patent Bioactivity Data | |
2. | ALA5052967 | F | Antiinflammatory activity in C57BL/6 mouse model of collagen-induced arthritis assessed as reduction in clinical score at 0.25 mg, ip | Mus musculus | 4 | ALA5052828 | organism-based format | Patent Bioactivity Data | |
3. | ALA5052968 | F | Antiinflammatory activity in C57BL/6 mouse model of collagen-induced arthritis assessed as reduction in serum IL-6 level at 0.25 mg, ip | Mus musculus | 4 | ALA5052828 | organism-based format | Patent Bioactivity Data | |
4. | ALA5052969 | F | Antiinflammatory activity in C57BL/6 mouse model of collagen-induced arthritis assessed as reduction in frequency of CD4+ IL-17+ cells at 0.25 mg, ip | Mus musculus | 4 | ALA5052828 | organism-based format | Patent Bioactivity Data | |
5. | ALA5052970 | F | Protection against imiquimod-induced psoriasis model of BALB/c mouse assessed as reduction in clinical score at 1 mg treated topically | Mus musculus | 4 | ALA5052828 | organism-based format | Patent Bioactivity Data | |
6. | ALA5052971 | F | Protection against imiquimod-induced psoriasis model of BALB/c mouse assessed as reduction in IL-6 mRNA expression at 1 mg treated topically | Mus musculus | 4 | ALA5052828 | organism-based format | Patent Bioactivity Data | |
7. | ALA5052972 | F | Protection against imiquimod-induced psoriasis model of BALB/c mouse assessed as reduction in IL-17a mRNA expression at 1 mg treated topically | Mus musculus | 4 | ALA5052828 | organism-based format | Patent Bioactivity Data | |
8. | ALA5052973 | F | Antiproliferative activity against human MDA-MB-231 cells after 4 hrs by CCK-8 assay | Homo sapiens | 4 | ALA5052828 | cell-based format | Patent Bioactivity Data | |
9. | ALA5052974 | F | Antiproliferative activity against human LNCaP cells after 4 hrs by CCK-8 assay | Homo sapiens | 4 | ALA5052828 | cell-based format | Patent Bioactivity Data | |
10. | ALA5052975 | F | Antiproliferative activity against human A549 cells after 4 hrs by CCK-8 assay | Homo sapiens | 4 | ALA5052828 | cell-based format | Patent Bioactivity Data | |
11. | ALA5052976 | F | Antiproliferative activity against human MDA-MB-231 cells at 20 uM assessed as suppression of cell viability after 4 hrs by CCK-8 assay | Homo sapiens | 4 | ALA5052828 | cell-based format | Patent Bioactivity Data | |
12. | ALA5052977 | F | Antiproliferative activity against human LNCaP cells at 25 uM assessed as suppression of cell viability after 4 hrs by CCK-8 assay | Homo sapiens | 4 | ALA5052828 | cell-based format | Patent Bioactivity Data | |
13. | ALA5052978 | F | Antiproliferative activity against human A549 cells at 20 uM assessed as suppression of cell viability after 4 hrs by CCK-8 assay | Homo sapiens | 4 | ALA5052828 | cell-based format | Patent Bioactivity Data |